Clash Of The LVADs: Continuous Flow Devices Moved To Lower-Paying DRG
This article was originally published in The Gray Sheet
Executive Summary
MicroMed is seeking to regain sufficient inpatient reimbursement for its DeBakey left-ventricular assist device by the time Medicare coverage for LVADs as destination therapy becomes effective
You may also be interested in...
MicroMed DeBakey Trial Ready To Begin Following CMS Payment Change
CMS' decision to reimburse axial flow left-ventricular assist devices at the same rate as positive displacement LVADs resulted from meetings between the agency and system developers and researchers, MicroMed says
MicroMed DeBakey Trial Ready To Begin Following CMS Payment Change
CMS' decision to reimburse axial flow left-ventricular assist devices at the same rate as positive displacement LVADs resulted from meetings between the agency and system developers and researchers, MicroMed says
Thoratec Plans HeartMate II Trial In 2004, HeartMate III Study In 2005
Thoratec is proposing a pivotal clinical trial design incorporating both heart transplant candidates and destination left-ventricular assist device therapy patients to evaluate the HeartMate II LVAD